Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financi...(173 245 Total costs and exp...)

Date:3/26/2009

173 245 Total costs and expenses 54,239 25,630 Income from operations 10,628 2,441 Other expenses: Interest expense, net (1,211) (1,410) Loss on marketable security (8) (323) Other expenses (2) (8) Total other expenses (1,221) (1,741) Income before income taxes 9,407 700 Provision for income taxes (414) (130) Net income $8,993 $570 Net income per share, basic $1.29 $0.10 Net income per share, diluted $1.14 $0.08 Weighted-average common shares, basic 6,951,896 5,934,496 Weighted-average common shares, diluted 7,861,119 6,751,127 CORNERSTONE THERAPEUTICS INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) Year Ended December 31, 2008 2007 Assets Current assets: Cash and cash equivalents $9,286 $241 Marketable securities 300 8 Accounts receivable, net 13,660 6,529 Amounts due from related parties - 648 Inventories, net 11,222 2,998 Prepaid expenses 1,081 278 Deferred income tax asset 2,428 - Total current assets 37,977 10,702 Property and eq
'/>"/>

SOURCE Cornerstone Therapeutics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference